Optimizing clozapine treatment

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 12, 1999, Pages 35-38

  Naber, Dieter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL;

AGRANULOCYTOSIS; BLOOD TOXICITY; CARDIOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HYPERSALIVATION; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK BENEFIT ANALYSIS; SELF EVALUATION; SKIN TOXICITY; WEIGHT GAIN; WELLBEING;

EID: 0032982118     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Fleischhacker WW, Meise U, Gunther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994; 89(suppl 382):11-15
2. Blair DT, Dauner A. Extrapyramidal symptoms are serious side-effects of antipsychotic and other drugs. Nurse Pract 1992;17:56
3. Peacock L, Solgaard T, Lublin H, et al. Clozapine versus typical antipsychotics: a retro-and prospective study of extrapyramidal side effects. Psychopharmacology (Berl) 1996;124:188-196
4. Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998;59:69-75
5. Rifkin A. Extrapyramidal side effects: a historical perspective. J Clin Psychiatry 1987;48(9, suppl):3-6
6. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationship to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(suppl 3): 133-138
7. Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-897
8. Naber D, Leppig M, Grohmann R, et al. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia: a retrospective study of 387 patients. Psychopharmacology (Berl) 1989;99 (suppl):S73-S76
9. Naber D, Hippius H. The European experience with use of clozapine. Hosp Community Psychiatry 1990;41:886-890
10. Naber D, Holzbach R, Perro C, et al. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 1992;160 (suppl 17):54-59
11. Hirsch SR, Puri BK. Clozapine: progress in treating refractory schizophrenia. BMJ 1993;306:1427-1428
12. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry 1994;55:44-49
13. Safferman A, Lieberman JA, Kane JM, et al. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991;17:247-261
14. Lieberman J, Safferman A, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-1752
15. Miller SC. Methylphenidate for clozapine sedation. Am J Psychiatry 1996; 153:1231-1232
16. Rosenheck R, Tekell J, Peters J, et al. Does participation in psychosocial treatment augment the benefit of clozapine? Arch Gen Psychiatry 1998; 55:618-625